Geoff Meacham
Stock Analyst at Citigroup
(4.23)
# 336
Out of 5,178 analysts
294
Total ratings
57.22%
Success rate
11.66%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Maintains: Buy | $95 → $125 | $79.62 | +57.00% | 3 | Mar 24, 2026 | |
| MRK Merck & Co. | Maintains: Neutral | $120 → $125 | $119.84 | +4.31% | 12 | Mar 20, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $115 → $125 | $104.50 | +19.62% | 5 | Mar 19, 2026 | |
| BNTX BioNTech SE | Maintains: Buy | $145 → $130 | $88.68 | +46.59% | 3 | Mar 11, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $97 → $85 | $55.83 | +52.26% | 4 | Mar 11, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $575 → $585 | $456.71 | +28.09% | 7 | Mar 10, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $55 → $58 | $45.20 | +28.32% | 2 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $110 → $120 | $80.33 | +49.38% | 8 | Mar 2, 2026 | |
| MANE Veradermics | Initiates: Buy | $85 | $68.71 | +23.71% | 1 | Mar 2, 2026 | |
| ACLX Arcellx | Downgrades: Neutral | $110 → $115 | $114.50 | +0.44% | 2 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $13.58 | +39.91% | 6 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $215 | $190.38 | +12.93% | 19 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $64 | $59.12 | +8.25% | 9 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $315 → $345 | $352.92 | -2.24% | 14 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $235 → $230 | $209.37 | +9.85% | 22 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $156 | $138.20 | +12.88% | 9 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $50 | $47.44 | +5.40% | 4 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $13.23 | +277.93% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $49 | $13.78 | +255.59% | 3 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $26 | $27.65 | -5.97% | 7 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $8 | $2.62 | +205.34% | 6 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $75 | $67.35 | +11.36% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $700 | $757.39 | -7.58% | 24 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $28 | $53.92 | -48.07% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $31.07 | +60.93% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $50 | $46.81 | +6.81% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $93 | $48.13 | +93.23% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $14 | $9.02 | +55.21% | 3 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $54 | $71.89 | -24.89% | 6 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $6 | $9.12 | -34.21% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $1 | $2.57 | -61.09% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $112 → $4 | $1.39 | +188.81% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $904.18 | +21.66% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $120 → $20 | $20.53 | -2.58% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $37.84 | -18.08% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $240.60 | -29.34% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $1.09 | +1,459.63% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $1.55 | +1,448.39% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $10.57 | -62.16% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $15.54 | +80.18% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.05 | +1,558.54% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $2.76 | +1,168.12% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.38 | +2,954.55% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $7.96 | +151.26% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $0.35 | +5,687.04% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $6.31 | +42.63% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $8.47 | +608.38% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $24.69 | -6.83% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $92.81 | -11.65% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $536.15 | -82.28% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $20.50 | +290.24% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $132.49 | +1.89% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.45 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $3.20 | +525.00% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $8.90 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $331.46 | -52.33% | 5 | Nov 8, 2017 |
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $95 → $125
Current: $79.62
Upside: +57.00%
Merck & Co.
Mar 20, 2026
Maintains: Neutral
Price Target: $120 → $125
Current: $119.84
Upside: +4.31%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Buy
Price Target: $115 → $125
Current: $104.50
Upside: +19.62%
BioNTech SE
Mar 11, 2026
Maintains: Buy
Price Target: $145 → $130
Current: $88.68
Upside: +46.59%
BioMarin Pharmaceutical
Mar 11, 2026
Maintains: Buy
Price Target: $97 → $85
Current: $55.83
Upside: +52.26%
Vertex Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $575 → $585
Current: $456.71
Upside: +28.09%
Scholar Rock Holding
Mar 4, 2026
Maintains: Buy
Price Target: $55 → $58
Current: $45.20
Upside: +28.32%
Kymera Therapeutics
Mar 2, 2026
Maintains: Buy
Price Target: $110 → $120
Current: $80.33
Upside: +49.38%
Veradermics
Mar 2, 2026
Initiates: Buy
Price Target: $85
Current: $68.71
Upside: +23.71%
Arcellx
Feb 24, 2026
Downgrades: Neutral
Price Target: $110 → $115
Current: $114.50
Upside: +0.44%
Feb 20, 2026
Maintains: Buy
Price Target: $15 → $19
Current: $13.58
Upside: +39.91%
Feb 9, 2026
Maintains: Neutral
Price Target: $185 → $215
Current: $190.38
Upside: +12.93%
Feb 6, 2026
Maintains: Neutral
Price Target: $60 → $64
Current: $59.12
Upside: +8.25%
Feb 4, 2026
Maintains: Neutral
Price Target: $315 → $345
Current: $352.92
Upside: -2.24%
Jan 27, 2026
Maintains: Neutral
Price Target: $235 → $230
Current: $209.37
Upside: +9.85%
Jan 27, 2026
Maintains: Buy
Price Target: $140 → $156
Current: $138.20
Upside: +12.88%
Jan 27, 2026
Maintains: Buy
Price Target: $48 → $50
Current: $47.44
Upside: +5.40%
Jan 9, 2026
Initiates: Buy
Price Target: $50
Current: $13.23
Upside: +277.93%
Dec 2, 2025
Maintains: Buy
Price Target: $58 → $49
Current: $13.78
Upside: +255.59%
Dec 2, 2025
Reinstates: Neutral
Price Target: $26
Current: $27.65
Upside: -5.97%
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.62
Upside: +205.34%
Nov 5, 2025
Maintains: Neutral
Price Target: $50 → $75
Current: $67.35
Upside: +11.36%
Oct 29, 2025
Maintains: Buy
Price Target: $660 → $700
Current: $757.39
Upside: -7.58%
Oct 23, 2025
Maintains: Neutral
Price Target: $30 → $28
Current: $53.92
Upside: -48.07%
Oct 17, 2025
Maintains: Buy
Price Target: $42 → $50
Current: $31.07
Upside: +60.93%
Oct 17, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $46.81
Upside: +6.81%
Oct 17, 2025
Maintains: Buy
Price Target: $78 → $93
Current: $48.13
Upside: +93.23%
Aug 27, 2025
Upgrades: Buy
Price Target: $12 → $14
Current: $9.02
Upside: +55.21%
Jun 25, 2025
Maintains: Buy
Price Target: $50 → $54
Current: $71.89
Upside: -24.89%
Jun 17, 2025
Initiates: Sell
Price Target: $6
Current: $9.12
Upside: -34.21%
Apr 2, 2025
Downgrades: Underperform
Price Target: $7 → $1
Current: $2.57
Upside: -61.09%
Jan 7, 2025
Downgrades: Underperform
Price Target: $112 → $4
Current: $1.39
Upside: +188.81%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $904.18
Upside: +21.66%
Oct 30, 2024
Downgrades: Underperform
Price Target: $120 → $20
Current: $20.53
Upside: -2.58%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $37.84
Upside: -18.08%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $240.60
Upside: -29.34%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $1.09
Upside: +1,459.63%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $1.55
Upside: +1,448.39%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $10.57
Upside: -62.16%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $15.54
Upside: +80.18%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $2.05
Upside: +1,558.54%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $2.76
Upside: +1,168.12%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.38
Upside: +2,954.55%
Sep 15, 2020
Reinstates: Buy
Price Target: $20
Current: $7.96
Upside: +151.26%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $0.35
Upside: +5,687.04%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $6.31
Upside: +42.63%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $8.47
Upside: +608.38%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $24.69
Upside: -6.83%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $92.81
Upside: -11.65%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $536.15
Upside: -82.28%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $20.50
Upside: +290.24%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $132.49
Upside: +1.89%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $9.45
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $3.20
Upside: +525.00%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $8.90
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $331.46
Upside: -52.33%